2004 Summer Meeting - Amsterdam - The Pathological Society of ...
2004 Summer Meeting - Amsterdam - The Pathological Society of ...
2004 Summer Meeting - Amsterdam - The Pathological Society of ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
157<br />
Oxaliplatin Toxicity In <strong>The</strong> Liver<br />
J A Kitchen , A McGregor<br />
Histopathology department, University Hospitals <strong>of</strong> Leicester NHS Trust,<br />
Leicester, United Kingdom<br />
Guidance issued by NICE in March 2002 recommends that oxaliplatin should<br />
be considered for use (in combination with 5FU/FA) in pre-operative<br />
chemotherapy to downstage potentially resectable colorectal carcinoma<br />
metastases in the liver. <strong>The</strong>re is no literature on oxaliplatin hepatotoxicity<br />
except for a mention <strong>of</strong> altered serum liver enzyme and bilirubin chemistry in<br />
the manufacturer’s datasheet. However, consequent to our own anecdotal<br />
observations, we propose that oxaliplatin causes steatosis in the liver.<br />
Identifying possible hepatotoxicity is important, as steatosis may complicate the<br />
radiological assessment, and therefore also clinical management, <strong>of</strong> disease<br />
progression.<br />
We identified ten patients with post-oxaliplatin chemotherapy liver resections<br />
or biopsies, and a cohort <strong>of</strong> age, sex, and disease-matched patients who had not<br />
received oxaliplatin. Histological features <strong>of</strong> steatohepatitis were graded<br />
semiquantitatively.<br />
Steatosis was noted in 80% <strong>of</strong> the ‘oxaliplatin group’, including one<br />
patient with no fatty changes in a pre-chemotherapy biopsy, but moderate<br />
steatosis in a post-oxaliplatin resection specimen. <strong>The</strong> prevalence <strong>of</strong> steatosis in<br />
liver transplant donors is reported at 13-25% and 30% <strong>of</strong> cases in our control<br />
group showed steatosis.<br />
We conclude that oxaliplatin chemotherapy can cause steatosis in<br />
the liver <strong>of</strong> patients with metastatic colorectal carcinoma, a feature that may<br />
complicate subsequent radiological and clinical assessment.<br />
158<br />
Immunohistochemical study on L-type amino acid transporter<br />
1(LAT1) expression for myelodysplastic syndrome<br />
I. Saito 1 , K. Taki 1 , A. Sakamoto 2<br />
1 Musashino Red Cross Hospital, Tokyo, Japan, 2 Kyorin University<br />
School <strong>of</strong> Medicine, Tokyo, Japan<br />
Background: L-type amino acid transporter 1(LAT1) is one <strong>of</strong> the protein<br />
which plays as a transporter <strong>of</strong> amino acid for cell proliferation. In this study,<br />
we examined immunohistochemical expression for LAT1 using human bone<br />
marrow tissue with myelodysplastic syndrome.<br />
Materials and Methods: We use 26 case tissue specimens <strong>of</strong> clinically and<br />
histologically confirmed myelodysplastic syndrome (MDS) (FAB<br />
classification) (13 refractory anaemia: RA, 7 RA with excess <strong>of</strong> blasts: RAEB,<br />
6 RAEB in transformation: RAEB-T cases). Immunohistochemical study was<br />
done by anti-LAT1 monoclonal antibody. Evaluation was given 3 categories,<br />
namely, strongly positive, weekly positive and negative.<br />
Results and Discussion: Positive immunoreactivity was found in the<br />
cytoplasm and cell membrane <strong>of</strong> immature myeloid blats. As to MDS, 25 cases<br />
(96.2%) revealed strongly positive and weakly positive. One case showed<br />
negative (4.8%). More than 90% <strong>of</strong> MDS cases showed immunohistochemical<br />
reactivity. <strong>The</strong>refore, our data suggest a close relationship between LAT1 and<br />
neoplastic lesions <strong>of</strong> bone marrow. We believe that LAT1 immunoreactivity<br />
can be applied for histodiagnosis <strong>of</strong> MDS as a useful tool.<br />
159<br />
Clinical And Laboratory Presentation Of Chronic<br />
Lymphocytic Leukaemia<br />
L A Sanni , S O'Connor , A Jack<br />
Department <strong>of</strong> Histopathology, Algernon Firth Building, <strong>The</strong> General<br />
Infirmary at Leeds, Leeds LS1 3EX, Leeds, United Kingdom<br />
Patients with chronic lymphocytic leukaemia (CLL), the most common adult<br />
leukaemia in the western world, can either be asymptomatic or present with<br />
lymphadenopathy, hepatosplenomegaly, and non-specific symptoms <strong>of</strong> easy<br />
fatigability, weight loss and anorexia. <strong>The</strong> diagnosis is <strong>of</strong>ten made by lymph<br />
node (LN) biopsy or an absolute lymphocytosis greater than 5000 x 10 9 /L.<br />
However, the mode <strong>of</strong> clinical and laboratory presentation is a subject <strong>of</strong><br />
controversy. We studied 67 patients (44 men and 23 women) with a primary<br />
diagnosis <strong>of</strong> CLL, made on a LN or other solid tissue. <strong>The</strong> median age <strong>of</strong><br />
diagnosis was 70y (range 35 – 87y). Many patients had a raised lymphocyte<br />
count and LN biopsy was not essential for diagnosis. In 22% <strong>of</strong> cases (14/65),<br />
CLL was diagnosed incidentally during investigation for other malignancies.<br />
Almost all cases had a variable degree <strong>of</strong> marrow involvement (range 5-100%).<br />
<strong>The</strong> immunophenotype <strong>of</strong> IgM/D+, CD5+, CD79+weak, CD20+weak, CD23+,<br />
CD19+, CD22+, FMC7-, CD38- was present in 75% (50/67) <strong>of</strong> cases. ATM<br />
deletion, a poor prognostic marker, was present in 30% (7/23) <strong>of</strong> cases, when<br />
looked for.<br />
Our data suggest that even in patients with lymphadenopathy, diagnosis can<br />
be made on peripheral blood and marrow examination without recourse to LN<br />
biopsy.<br />
160<br />
Study <strong>of</strong> Plasmacytoid Dendritic Cells in Lymph Nodes<br />
Draining Breast Cancer by CD 123 Antibody. An<br />
Immunohistochemical and Flow Cytometry Study<br />
K Cox 1 , N M Aqel 2 , F Facchetti 4 , H Singhal 3 , M Burke 3 , S<br />
C Knight 1<br />
1 Antigen Presentation Group, Imperial College, Harrow, United<br />
Kingdom, 2 Department <strong>of</strong> Cellular Pathology, Northwick Park Hospital,<br />
Harrow, United Kingdom, 3 Directorate <strong>of</strong> Surgery, Northwick Park<br />
Hospital, Harrow, United Kingdom, 4 Department <strong>of</strong> Pathology II,<br />
Brescia, Italy<br />
Plasmacytoid dendritic cells (PDC) constitute a distinct subset <strong>of</strong> antigen<br />
presenting cells. Morphologically similar cells can be found in histological<br />
sections <strong>of</strong> reactive lymph nodes (LN), close to High Endothelial Venules<br />
(HEV) in LN paracortex.<br />
We examined PDC in axillary LNs draining breast carcinoma by using an<br />
anti-CD123 antibody, both immunohistochemically on paraffin sections and<br />
flow cytometry. Paraffin sections from one LN <strong>of</strong> each patient were<br />
immunostained for CD 123. Cell suspensions were made from one fresh LN<br />
from each patient and then flow cytometry was employed to identify and isolate<br />
PDC. By using four-colour flow cytometry, PDC in axillary LN (n=19) were<br />
consistently identified. PDC are positive for HLA-DR & CD123 (high). <strong>The</strong>y<br />
are negative for CD3, CD14, CD16, CD19, CD34, CD56 & CD11c. PDC<br />
stained strongly for CD123 in sections <strong>of</strong> LNs and were found in LN paracortex<br />
and scattered discretely in lymph node sinus system.<br />
Our findings suggest that: 1. Flow cytometry can be a useful tool in isolating<br />
PDC from LN, which can then be used in various functional studies 2. PDC<br />
have been identified, for first time, in paraffin sections <strong>of</strong> LNs draining breast<br />
carcinoma using anti-CD123 antibody 3. Identification <strong>of</strong> PDC in LN<br />
paracortex, discretely and close to HEV, confirms previous data on the<br />
localization <strong>of</strong> these cells in reactive LN 4. <strong>The</strong> identification <strong>of</strong> PDC in LN<br />
sinuses strongly suggests that at least some PDC migrate to LNs through the<br />
afferent lymphatics.<br />
66